2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 8.202 | 9.704 | 17.730 | 24.969 | 31.442 | 59.871 | 42.206 | 58.989 | 58.423 | 130.444 |
Total Income - EUR | 8.202 | 18.703 | 17.730 | 46.860 | 66.739 | 62.784 | 59.284 | 93.404 | 104.542 | 224.709 |
Total Expenses - EUR | 15.638 | 14.269 | 28.050 | 43.928 | 64.607 | 59.682 | 46.018 | 73.359 | 75.341 | 204.118 |
Gross Profit/Loss - EUR | -7.436 | 4.434 | -10.320 | 2.932 | 2.133 | 3.101 | 13.265 | 20.045 | 29.201 | 20.591 |
Net Profit/Loss - EUR | -7.682 | 4.143 | -10.497 | 2.647 | 1.789 | 2.387 | 12.645 | 19.524 | 28.698 | 18.950 |
Employees | 3 | 2 | 2 | 4 | 6 | 6 | 5 | 6 | 9 | 11 |
Check the financial reports for the company - Diaderin Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1.551 | 8.663 | 7.715 | 7.814 |
Current Assets | 5.684 | 6.623 | 1.499 | 5.314 | 49.795 | 45.157 | 48.326 | 78.552 | 193.980 | 207.736 |
Inventories | 5.098 | 5.564 | 552 | 1.028 | 39.189 | 40.508 | 47.650 | 77.725 | 189.011 | 199.184 |
Receivables | 46 | 63 | 93 | 4.108 | 7.874 | 3.624 | 484 | 593 | 4.719 | 8.196 |
Cash | 540 | 995 | 854 | 178 | 2.732 | 1.024 | 191 | 234 | 250 | 355 |
Shareholders Funds | -16.039 | -12.030 | -10.452 | -7.629 | -5.699 | -3.202 | 9.723 | 29.180 | 57.968 | 76.742 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 21.723 | 18.652 | 11.952 | 12.942 | 55.494 | 48.359 | 40.153 | 58.036 | 143.727 | 138.807 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "1623 - 1623" | |||||||||
CAEN Financial Year |
1623
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Diaderin Srl